Syros Pharmaceuticals (NASDAQ: SYRS) and ChemoCentryx (NASDAQ:CCXI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
This table compares Syros Pharmaceuticals and ChemoCentryx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Syros Pharmaceuticals and ChemoCentryx’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Syros Pharmaceuticals||$320,000.00||1,051.20||-$47.74 million||($2.01)||-5.20|
|ChemoCentryx||$11.94 million||39.05||-$39.96 million||($0.60)||-15.93|
ChemoCentryx has higher revenue and earnings than Syros Pharmaceuticals. ChemoCentryx is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
48.8% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.4% of ChemoCentryx shares are owned by institutional investors. 33.6% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 26.2% of ChemoCentryx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility & Risk
Syros Pharmaceuticals has a beta of -2.36, indicating that its share price is 336% less volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Syros Pharmaceuticals and ChemoCentryx, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Syros Pharmaceuticals currently has a consensus target price of $23.83, indicating a potential upside of 128.08%. Given Syros Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Syros Pharmaceuticals is more favorable than ChemoCentryx.
Syros Pharmaceuticals beats ChemoCentryx on 7 of the 12 factors compared between the two stocks.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.